Inflammatory bowel disease in Korea: epidemiology and pathophysiology

1. Im JP, Ye BD, Kim YS, Kim JS. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med 2018;33:28–35.
crossref pmid pmc pdf
2. Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med 2018;33:20–27.
crossref pmid pmc pdf
3. Lee J, Im JP, Han K, et al. Changes in direct healthcare costs before and after the diagnosis of inflammatory bowel disease: a nationwide population-based study. Gut Liver 2020;14:89–99.
crossref pmid pmc
4. Kim JW, Lee CK, Rhee SY, Oh CH, Shim JJ, Kim HJ. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: a nationwide population-based study. J Gastroenterol Hepatol 2018;33:847–854.
crossref pmid pdf
5. Yen HH, Weng MT, Tung CC, et al. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population based study. Intest Res 2019;17:54–62.
crossref pmid pmc pdf
6. Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986–2015. J Crohns Colitis 2019;13:1410–1417.
crossref pmid pdf
7. Cha JM, Park SH, Rhee KH, et al. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut 2020;69:1432–1440.
crossref pmid
8. Cheon JH, Kim YS, Ye BD, et al. Crohn’s Disease Clinical Network and Cohort (CONNECT) Study: the first step toward nationwide multicenter research of Crohn’s disease in Korea. Intest Res 2014;12:173–175.
crossref pmid pmc
9. Lee JW, Im JP, Cheon JH, Kim YS, Kim JS, Han DS. Inflammatory bowel disease cohort studies in Korea: present and future. Intest Res 2015;13:213–218.
crossref pmid pmc
10. Moon CM, Jung SA, Kim SE, et al. Clinical factors and disease course related to diagnostic delay in Korean Crohn’s disease patients: results from the CONNECT Study. PLoS One 2015;10:e0144390.
crossref pmid pmc
11. Ye BD, Hong SN, Seo SI, et al. Changes in the long-term prognosis of Crohn’s disease between 1986 and 2015: the population-based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study. Gut Liver 2022;16:216–227.
crossref pmid pmc
12. Yoon JY, Cha JM, Lee CK, et al. Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: results from a hospital-based inception cohort study (MOSAIK). J Gastroenterol Hepatol 2021;36:2149–2156.
crossref pmid pdf
13. Yoon JS, Lee SJ, Kim ES, et al. Quality of information on the Internet for Korean patients with inflammatory bowel disease. Korean J Intern Med 2019;34:1215–1222.
crossref pmid pmc pdf
14. Park J, Park S, Lee SA, Park SJ, Cheon JH. Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management. Korean J Intern Med 2021;36:1040–1048.
crossref pmid pmc pdf
15. Hong SW, Ye BD. The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia. Intest Res 2020;18:345–346.
crossref pmid pmc pdf
16. Song EM, Yang SK. Natural history of inflammatory bowel disease: a comparison between the East and the West. Intest Res 2021. Dec. 2. [Epub]. https://doi.org/10.5217/ir.2021.00104 .
crossref pmid
17. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56–66.
crossref pmid pmc pdf
18. Aniwan S, Limsrivilai J, Pongprasobchai S, et al. Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018. Intest Res 2021;19:186–193.
crossref pmid pmc pdf
19. Kaibullayeva J, Ualiyeva A, Oshibayeva A, Dushpanova A, Marshall JK. Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. Intest Res 2020;18:430–437.
crossref pmid pmc pdf
20. Sood A, Kaur K, Mahajan R, et al. Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry. Intest Res 2021;19:206–216.
crossref pmid pmc pdf
21. Kwak MS, Cha JM, Lee HH, et al. Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study. J Gastroenterol Hepatol 2019;34:1018–1026.
crossref pmid pdf
22. Korean Association for the Study of Intestinal Diseases. 2020 Inflammatory bowel disease fact sheet in Korea [Internet] Seoul (KR): Korean Association for the Study of Intestinal Diseases, 2020. [cited 2022 Jul 11]. Available from: http://m.kasid.org/file/IBM/IBD%20fact%20sheet_1217.pdf . 23. Lee CK, Ha HJ, Oh SJ, et al. Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. J Gastroenterol Hepatol 2020;35:760–768.
crossref pmid pdf
24. Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in incidence of inflammatory bowel diseases: pooled analysis of population-based studies from Western countries. Gastroenterology 2018;155:1079–1089.
crossref pmid
25. Kim J, Ye BD. Successful transition from pediatric to adult care in inflammatory bowel disease: what is the key? Intest Res 2019;17:24–35.
crossref pmid pmc pdf
26. Banerjee R, Pal P, Nabi Z, Shava U, Ganesh G, Reddy DN. Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease. Intest Res 2021;19:398–407.
crossref pmid pmc pdf
27. Park SH, Im JP, Park H, et al. Clinical features and long-term outcomes of paediatric-onset inflammatory bowel disease in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. J Crohns Colitis 2022;16:207–215.
crossref pmid pdf
28. Singh S, Picardo S, Seow CH. Management of inflammatory bowel diseases in special populations: obese, old, or obstetric. Clin Gastroenterol Hepatol 2020;18:1367–1380.
crossref pmid pmc
29. Shi HY, Chan FK, Leung WK, et al. Natural history of elderly-onset ulcerative colitis: results from a Territory-wide Inflammatory Bowel Disease Registry. J Crohns Colitis 2016;10:176–185.
crossref pmid
30. Park SH, Jeong SK, Lee JH, et al. Clinical characteristics and long-term prognosis of elderly-onset ulcerative colitis in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut Liver 2021;15:742–751.
crossref pmid pmc
31. Song EM, Lee HS, Park SH, et al. Clinical characteristics and long-term prognosis of elderly onset ulcerative colitis. J Gastroenterol Hepatol 2018;33:172–179.
crossref pmid pdf
32. Hwang SW, Kwak MS, Kim WS, et al. Influence of a positive family history on the clinical course of inflammatory bowel disease. J Crohns Colitis 2016;10:1024–1032.
crossref pmid
33. Jung YS, Park DI, Ye BD, et al. Long-term clinical outcomes of urban versus rural environment in Korean patients with Crohn’s disease: results from the CONNECT study. J Crohns Colitis 2015;9:246–251.
crossref pmid
34. Choe JY, Choi S, Song KH, et al. Incidence and prevalence trends of pediatric inflammatory bowel disease in the Daegu-Kyungpook province from 2017 to 2020. Front Pediatr 2022;9:810173.
crossref pmid pmc
35. Lee EJ, Kim TO, Song GA, et al. Clinical features of Crohn’s disease in Korean patients residing in Busan and Gyeongnam. Intest Res 2016;14:30–36.
crossref pmid pmc
36. Han M, Jung YS, Cheon JH, Park S. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1166–1174.
crossref pmid pdf
37. Limsrivilai J, Pausawasdi N. Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases. Intest Res 2021;19:21–32.
crossref pmid pmc pdf
38. Lee HS, Choe J, Lee HJ, et al. Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea. Intest Res 2016;14:258–263.
crossref pmid pmc
39. Banerjee R, Ali RA, Wei SC, Adsul S. Biologics for the management of inflammatory bowel disease: a review in tuberculosis-endemic countries. Gut Liver 2020;14:685–698.
crossref pmid pmc
40. Hong HS, Jung J, Park SH, et al. Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases. Korean J Intern Med 2022;37:73–84.
crossref pmid pmc pdf
41. Park SH, Yang SK, Lim YS, et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis 2012;18:2004–2010.
crossref pmid
42. Park SK, Choi CH, Chun J, et al. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res 2020;18:18–33.
crossref pmid pmc pdf
43. Lee HS, Park SH, Kim SH, et al. Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis. Inflamm Bowel Dis 2016;22:912–918.
crossref pmid
44. Park SH, Yang SK, Hong SM, et al. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci 2013;58:3592–3599.
crossref pmid pdf
45. Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and natural history of perianal Crohn’s disease: a systematic review and meta-analysis of population-based cohorts. Inflamm Bowel Dis 2021. Nov. 18. [Epub]. https://doi.org/10.1093/ibd/izab287 .
crossref pmid
46. Chun J, Im JP, Kim JW, et al. Association of perianal fistulas with clinical features and prognosis of Crohn’s disease in Korea: results from the CONNECT Study. Gut Liver 2018;12:544–554.
crossref pmid pmc
47. Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn’s disease in Korea. Scand J Gastroenterol 2010;45:1178–1185.
crossref pmid
48. Yoon JY, Cheon JH, Park SJ, Kim TI, Kim WH. Effects of perianal involvement on clinical outcomes in Crohn’s disease over 10 years. Gut Liver 2018;12:297–305.
crossref pmid pmc
49. Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. Intest Res 2020;18:249–264.
crossref pmid pmc pdf
50. Ha YJ, Kim HJ, Lee E, et al. Subclinical sacroiliitis detected by abdominopelvic computed tomography in Korean patients with Crohn’s disease. Korean J Intern Med 2021;36:868–877.
crossref pmid pmc
51. Yang BR, Choi NK, Kim MS, et al. Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients. PLoS One 2018;13:e0200363.
crossref pmid pmc
52. Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature 2020;578:527–539.
crossref pmid pmc pdf
53. Chen CJ, Hu H, Liao WT. Pathophysiology of inflammatory bowel diseases. N Engl J Med 2021;384:1376–1377.
crossref pmid
54. Mitsialis V, Wall S, Liu P, et al. Single-cell analyses of colon and blood reveal distinct immune cell signatures of ulcerative colitis and Crohn’s disease. Gastroenterology 2020;159:591–608.
crossref pmid pmc
55. Hong SN, Park C, Park SJ, et al. Deep resequencing of 131 Crohn’s disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants. Gut 2016;65:788–796.
crossref pmid
56. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell 2010;141:1135–1145.
crossref pmid pmc
57. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:979–986.
crossref pmid pmc pdf
58. Weiser M, Simon JM, Kochar B, et al. Molecular classification of Crohn’s disease reveals two clinically relevant subtypes. Gut 2018;67:36–42.
crossref pmid pmc
59. Nicolaides S, Vasudevan A, Long T, van Langenberg D. The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease. Intest Res 2021;19:158–170.
crossref pmid pmc pdf
60. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 2015;64:1063–1071.
crossref pmid
61. Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 2019;157:647–659.
crossref pmid
62. Roncoroni L, Gori R, Elli L, et al. Nutrition in patients with inflammatory bowel diseases: a narrative review. Nutrients 2022;14:751.
crossref pmid pmc
63. Levine A, Sigall Boneh R, Wine E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut 2018;67:1726–1738.
crossref pmid
64. Shafiee NH, Manaf ZA, Mokhtar NM, Raja Ali RA. Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? Intest Res 2021;19:171–185.
crossref pmid pmc pdf
65. Mizoguchi E, Low D, Ezaki Y, Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intest Res 2020;18:151–167.
crossref pmid pmc pdf
66. Read E, Curtis MA, Neves JF. The role of oral bacteria in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:731–742.
crossref pmid pdf
67. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520–1526.
crossref pmid
68. Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018;24:1868–1880.
crossref pmid pmc
69. Katsanos KH, Papadakis KA. Inflammatory bowel disease: updates on molecular targets for biologics. Gut Liver 2017;11:455–463.
crossref pmid pmc
70. Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 2017;14:269–278.
crossref pmid pdf
71. Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:323–337.
crossref pmid pdf
72. Nam SJ, Kim ES, Jeen YT. T-cell immune response against cytomegalovirus in peripheral blood and colonic mucosa from ulcerative colitis and Crohn’s disease patients. Intest Res 2018;16:160–162.
crossref pmid pmc pdf
73. Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. Nat Immunol 2014;15:1104–1115.
crossref pmid pmc pdf
74. Rampal R, Kedia S, Wari MN, et al. Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease. Intest Res 2021;19:232–238.
crossref pmid pmc pdf
75. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014;14:585–600.
crossref pmid pmc pdf
76. Lee JW, Lee SM, Chun J, et al. Novel histone deacetylase 6 inhibitor CKD-506 inhibits NF-κB signaling in intestinal epithelial cells and macrophages and ameliorates acute and chronic murine colitis. Inflamm Bowel Dis 2020;26:852–862.
crossref pmid pdf
77. Caruso R, Lo BC, Nunez G. Host-microbiota interactions in inflammatory bowel disease. Nat Rev Immunol 2020;20:411–426.
crossref pmid pdf
78. Iliev ID, Cadwell K. Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology 2021;160:1050–1066.
crossref pmid pmc
79. Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation, and colorectal cancer. Intest Res 2018;16:338–345.
crossref pmid pmc pdf
80. Park SK, Kim HN, Choi CH, et al. Differentially abundant bacterial taxa associated with prognostic variables of Crohn’s disease: results from the IMPACT Study. J Clin Med 2020;9:1748.
crossref pmid pmc
81. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146:1489–1499.
crossref pmid pmc
82. King SJ, McCole DF. Epithelial-microbial diplomacy: escalating border tensions drive inflammation in inflammatory bowel disease. Intest Res 2019;17:177–191.
crossref pmid pmc pdf
83. Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol 2019;17:497–511.
crossref pmid pmc pdf

留言 (0)

沒有登入
gif